196300.KQ HLB Pep Co., Ltd.
- Market cap
- KRW 35.7B
- P/E
- -
- P/B
- 1.55x
- ROE
- -32.5%
- Dividend yield
- -
- Fundamental score
- 0.5/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 196300.KQ undervalued?
Graham numberThe Graham number of HLB Pep Co., Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
HLB Pep Co., Ltd. fundamental analysis
3 of 21 checks passedROE 0/2
Low return on equity (-32.5%), below 10%.
ROA 0/1
Return on assets (-15.0%) is below the industry median (4.7%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (93.9%) is above the industry median (-16.9%).
Revenue Growth 0/2
Revenue shrank 17.0% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.1 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (1.6x) is above the industry median (0.6x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
HLB Pep Co., Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About HLB Pep Co., Ltd.
HLB Pep Co., Ltd., a bio-venture company, engages in the manufacture and sale of peptide biomaterials and drug raw materials in South Korea and internationally. It offers GMP, generic, custom, and catalog peptides, as well as offers other services. The company develops AGM-130, which is in Phase I for the treatment of triple negative breast cancer. In addition, its pre-clinical products include AGM-331 targeted for anti-cancer therapy; AGM-380 indicated for the treatment of …
Full company profileHLB Pep Co., Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
HLB Pep Co., Ltd. annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 8.66B | 5.61B | 6.23B | 4.96B | 5.80B |
| Gross Profit | 525M | -2.44B | -919M | -1.74B | -731M |
| Operating Income | -4.32B | -6.72B | -5.44B | -7.32B | -6.43B |
| EBITDA | -2.45B | -5.39B | -3.91B | 4.59B | -1.92B |
| Net Income | -6.20B | -9.08B | -6.79B | -642M | -7.47B |
| EPS | -1,107 | -1,529 | -1,132 | -69 | -804 |
| Balance Sheet | |||||
| Total Assets | 25.9B | 21.0B | 16.5B | 53.8B | 49.7B |
| Total Liabilities | 12.5B | 10.5B | 11.1B | 28.1B | 26.7B |
| Shareholders' Equity | 13.4B | 10.5B | 5.38B | 25.7B | 23.0B |
| Cash & Short-term Investments | 480M | 1.01B | 201M | 1.51B | 1.22B |
| Cash Flow | |||||
| Operating Cash Flow | -2.55B | -3.38B | -2.10B | -5.57B | -4.60B |
| Capital Expenditure | 1.93B | 655M | 476M | 5.43B | 4.87B |
| Free Cash Flow | -4.47B | -4.04B | -2.58B | -11.0B | -9.47B |
| Ratios | |||||
| ROE | -46.3% | -86.3% | -126.2% | -2.5% | -32.5% |
| ROA | -24.0% | -43.2% | -41.1% | -1.2% | -15.0% |
| Net Profit Margin | -71.6% | -161.8% | -109.1% | -12.9% | -128.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
HLB Pep Co., Ltd. dividends
HLB Pep Co., Ltd. has not paid dividends in the last 4 fiscal years.
Last stock split: 1.3:1 on Feb 28, 2024.
Who owns HLB Pep Co., Ltd.
- Insiders 47.72%
- Institutions 0.00%
- Public & others 52.28%
- Shares outstanding 9.38M
- Free float 5.14M
HLB Pep Co., Ltd. company profile
- Company name
- HLB Pep Co., Ltd.
- Ticker
- 196300.KQ
- Exchange
- KOSDAQ
- Sector
- Basic Materials
- Industry
- Chemicals
- Fiscal year end
- December
- Address
- Gwangju Technopark, Gwangju-si, South Korea, 61008
- Phone
- 82 6 2714 1166
- Website
- hlbpep.co.kr
About HLB Pep Co., Ltd.
HLB Pep Co., Ltd., a bio-venture company, engages in the manufacture and sale of peptide biomaterials and drug raw materials in South Korea and internationally. It offers GMP, generic, custom, and catalog peptides, as well as offers other services. The company develops AGM-130, which is in Phase I for the treatment of triple negative breast cancer. In addition, its pre-clinical products include AGM-331 targeted for anti-cancer therapy; AGM-380 indicated for the treatment of viral infection; and AGM-290 indicated for the treatment of infections caused by multidrug resistant bacteria. In addition, it is involved in the development of AGM-212 indicated for the treatment of Type 2 Diabetes; AGM-217 indicated for the treatment of Type 2 diabetes and obesity; and AGM-260 indicated for the treatment of Ulcerative colitis. The company was formerly known as Anygen Co., Ltd. and changed its name to HLB Pep Co., Ltd. in April 2025. The company was founded in 2000 and is headquartered in Gwangju-si, South Korea.
HLB Pep Co., Ltd. management
9- Mr. Jae Il KimCEO & Director
- Kyoung Jae ShimCEO & Director
- Ji-Yong ParkR&D Director & Director · born 1968
- Tae Il LeeDirector of Audit & Director
- You Deok KimExecutive Director
- YuDeok KimMD & Executive Director
- GukSang HwangManaging Director
- KyungNam KimDirector of Audit & Director
- Yeong Su JeonDirector of Audit & Director